DNA encoding recombinant lipoprotein antigens
US5786206A · kind A · utility
11Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 1994 |
| Grant date | Jul 28, 1998 |
| Priority date | — |
| Expiry date | Oct 31, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are described for determining the level of low density lipoproteins (LDL) in plasma. Native apoprotein B-100 (apo B-100) present in LDL particles is immunologically mimicked by a polypeptide of the invention. A polypeptide includes an amino acid residue sequence corresponding to a pan epitope region of the target apoprotein. A preferred polypeptide is a fusion protein that simultaneously mimics native apo B-100 and native apo A-I. Improved assay systems and methods for determining HDL and LDL levels in a body fluid sample are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.